The utility of prostate-specific antigen (PSA) screening for prostate cancer detection is impacted by detection of cancers with low risk of mortality. Editorialist Jeffrey J. Tosoian, MD, MPH, discusses a pragmatic approach to prostate cancer screening with JAMA Deputy Editor Mary L. (Nora) Disis, MD. Related Content:

• A Pragmatic Approach to Prostate Cancer Screening
• Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI
• Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality